No services found
No Products found
Contact us Talk to our experts
Looking for guaranteed fully human and blocking antibodies against your target?
Discover our 4 antibody discovery platforms (hybridoma, phage display, single B cell, AI based) to generate high-quality antibodies, in record time, no matter your target (small molecule, peptide, soluble protein, native membrane protein, DNA…).
Discover our platforms
Looking to discover next generation cancer immunotherapy?
Discover the world’s first immune phage display library derived from human cancer patient donors.
More Info
Seeking to develop a highly promising therapeutic antibody?
Revolutionize antibody Development with Single B Cell Sequencing.
Need a fast and cost-effective solution for monoclonal antibody development?
Accelerate your research with our fast-track protocol delivering high-affinity antibodies (up to 10^-12 M) in just 45 days.
Placeholder Text Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
You need help to determine the best solution for you between hybridoma development, antibody phage display and polyclonal antibody production?
Try the Antibody Quiz
Count on our highly specific and sensitive antibodies to accelerate your research and drug development.
Order now
Looking to discover next-generation cancer immunotherapy ?
Look no further than the world’s first immune phage display library derived from human cancer patient donors.
Discover now
Seeking to develop a highly promising therapeutic antibody? Access advanced technologies to generate high-affinity, low-immunogenicity candidates ready for clinical success.
Get the best start
Build highly specific CARs for your applications. Turn your concept into a powerful therapy with our expert-designed, fully customizable CAR solutions.
Learn more
Choose the right Conjugation Strategy for your Antibody Drug Conjugation Development. Maximize the therapeutic impact of your antibodies with expert-guided, tailored ADC solutions.
Select the right Bispecific antibody (BsAb) format generation to build your blockbuster.
Advance to the clinic with world-class experts and antibody humanization that enhances efficacy and reduces immunogenicity.
A complete portfolio of cancer products — biomarkers and antibodies — to accelerate your oncology research and discover new therapeutic pathways.
Order online
As a diagnostic company, you deserve antibodies with outstanding specificity, sensitivity, and stability—fully compatible with your application. We guarantee their performance in your assays.
Explore our custom solutions
High-affinity antibodies for low-abundance targets. We garantee they work in your application and in your lab.
Generate now
Boost your antibody’s affinity with our epitope mapping service—combining AI expertise and lab know-how to refine target interactions.
Boost now
Rely on us for your early-stage screening and diagnostic test prototyping. Five expression systems available, with scales from 1 to 4000 L.
More
Order your custom gene synthesis online. Our service is 100% sequence garanteed.
Find the right tools to detect and act on your target — antibodies, proteins, and reagents ready for your research.
Ensure consistency and scalability for your diagnostics — we develop stable cell lines tailored for robust, high-yield recombinant protein production.
Start now
Whether you need antibodies or proteins to understand, detect, validate, or test your research, our 100% custom antibodies services, and off-the-shelf products are here to support your fundamental or translational studies.
High-affinity antibodies for low-abundance targets. Validated in 11 applications. Performance guaranteed. Payment only upon success in your specific assay.
Trust experts to deliver high-yield molecule production in record time, so you can focus on your research. Five expression systems available, including E.coli, mammalian and insect cells.
High-quality peptides, starting at €1.66/aa. Customizable, competitive prices, and only pay if you’re satisfied!
Whether you’re developing novel biologics for livestock or companion animals, our platforms—phage display, hybridoma, and recombinant production—enable the generation of highly specific, stable, and species-adapted antibodies.
With proven expertise in veterinary targets and regulatory-grade deliverables, we support your path to safer, more effective animal therapies.
High-affinity antibodies in record time using our dog and cat phage display libraries — plus cost-effective solutions for other species.
Accelerate canine immunotherapy with LibAb-SFDog™ — the first high-diversity naïve dog antibody library, delivering top antibodies in under 7 weeks.
Unique on the market: get diverse, high-affinity cat antibodies in under 7 weeks from our ethical, animal-free phage display platform.
Rely on us for your transient protein and antibody expression needs. Five expression systems available, with scales from 1 to 4000 L.
Leveraging AI and lab expertise, we develop tailored, cost-effective antibody solutions for a wide variety of animal species.
Discover all the products you need to speed up your animal biomedicine’s journey to market with our extensive online store.
From gene synthesis to antibody bioproduction, our integrated services are designed to support your research at every step. Whether you’re just starting your project or scaling up for production, we provide tailored solutions to accelerate your progress and ensure continuity throughout your R&D journey. Tell us where you stand!
Book a Call Contact Us
Founded in 2003, ProteoGenix is specialized in integrated solutions from gene to biotherapeutics and diagnostics. ProteoGenix is the trusted partner for pharmaceutical and biotech companies seeking to develop custom assays and discover therapeutic antibodies. Our comprehensive suite of services includes:
From antigen design to hybridoma technology, phage display, and single B cell screening, we provide diverse and tailored approaches for generating high-quality antibodies.
We offer advanced antibody engineering services including humanization, affinity maturation, reformatting (e.g., bispecific antibodies, ADCs), and subtype or isotype switching.
Our expertise in recombinant monoclonal antibody production and stable cell line development ensures the reliable and scalable production of your therapeutic antibodies.
We offer protein expression across multiple systems, including E. coli, B. subtilis, yeast, insect cells, and mammalian cells, ensuring the right solution for your specific needs.
Tailored peptide synthesis services for your research and therapeutic development.
High-quality gene synthesis for your project requirements, from research to clinical applications.
Ensure confidence in your experiments with high-performance antibodies and proteins. With a catalog of 15,000+ products, we provide reliable solutions to accelerate your research and drug development. Get the right bioreagents, get faster results!
New
XtenCHO™ Race empowers researchers to produce the proteins they need—without the usual time and budget constraints. With XtenCHO™ Race, achieve outstanding yields; reaching up to 1.8 g/L; and fast timelines, with harvest possible as early as day 8.
Get the ready-to-use kit for only 1950€
Order online now
Research Area PD1-PDL1-PDL2
Discover antibodies capable of binding to either PD-1 or PD-L1, enabling the modulation of the immune response. This approach has been instrumental in developing cancer immunotherapies, as blocking the PD-1/PD-L1 interaction helps activate the body’s natural defense against cancer cells. Accelerate your research today!
Get your reagents
Visit the shop
Because your research deserves more than just a service, we offer a partnership built on scientific excellence, cutting-edge innovation, and ethical commitment—with dedicated experts by your side at every step.
Innovation
We dedicate a significant share of our revenue to R&D and continuously invest in state-of-the-art equipment to improve and expand our service offering.
AI-powered
Combine the power of state-of-the-art wet-lab techniques with advanced AI-driven solutions to whether you are looking to enhance your experimental designs or leverage AI for data analysis
Read more
40% of PhD Experts
All requests are handled by PhD-level experts who will manage the project from start to finish. They will be your point of contact throughout the entire project.
Meet the team
Ethic
We provide animal-free solutions, such as phage display technologies and AI-driven approaches, ensuring ethical and innovative alternatives for your projects.
For +20 years, ProteoGenix has proudly supported researchers worldwide in developing biotherapeutics and bio diagnostics. We cover every key stage of early-stage R&D — from discovery to engineering and production — offering seamless support with a single expert partner.
Based in France, with laboratories in Europe, a U.S. office in North Carolina, and a trusted partner in China, our global presence ensures fast and responsive service. Our experienced, customer-focused teams are committed to accelerating your projects and maximizing your chances of success.
Contact us
At ProteoGenix, we see ourselves as committed partners in our clients’ research, contributing to the success of their projects through expertise and close collaboration. Whether the mission is short or long-term, we approach each one with the same dedication. Active listening and tailored solutions are at the heart of our approach.
Because risk is part of any research journey, we include GO/NO-GO milestones and offer success-based guarantees. Our ISO 9001 and ISO 14001 certifications reflect our strong commitment to quality, sustainability, and customer satisfaction.
Don’t miss the chance to meet our experts at key industry congresses. Stay ahead of the curve, discuss your projects, and explore new opportunities for collaboration.
27.04-30.04.25
Chicago, USA
Meet our experts in Chicago at the most important cancer meeting in the world
04.05.-06.05.25
Honolulu, Hawaï
Join us Saturday, May 3 to Wednesday, May 7 in Honolulu for the leading annual all-immunology event worldwide
12.05.-15.05.25
Boston, USA
16.06.-19.06.25
Lisbon, Portugal
Follow us on
Discover how researchers and industry leaders worldwide achieve success with our antibody solutions. Hear their stories and see the impact of our expertise on groundbreaking projects.
National Cancer Centre, Singapore
Prof Johnny Ong Chin-Ann, MD, PhD, Group leader
“We have been working together with ProteoGenix since 2020. Using phage display, they helped our team to develop several antibodies with effective blocking effects. We are pleased with their services and look forward to continue working together with them as we advance our research and bring the biologics to the clinical stage.”
Birmingham University, UK
Dr. Julie Rayes, Associate Professor
“I contacted ProteoGenix regarding the generation of monoclonal antibodies for the detection of a chemokine. ProteoGenix generated for us multiple monoclonal antibodies to detect the chemokine by ELISA, western blot and to test these antibodies in functional assays. They provided an excellent service, with regular updates, quick response to our queries and an excellent delivery of the product. I recommend their service for their efficacy and professionalism.”
Brown University, USA
Prof Jonathan Kurtis, MD, PhD, Chair, Department of Pathology and Laboratory Medicine
“I requested ProteoGenix’s services for the generation of antibodies against a malarial protein by phage display. Their naive human library, which is comprised of 368 donors, is a unique resource which was one of the criteria I used to select their company. They optimized their standard screening strategy to be able to identify two specific clones, that they then expressed with very high yields in their proprietary XtenCHO™ cell line. I highly appreciated their level of expertise and their commitment to go beyond expectations, and I would recommend them for their reactivity and the high quality of their services.”
Telum Therapeutics, Spain
Verónica Alcolea, Development Manager
“We are thrilled with the success we’ve achieved through our collaboration with ProteoGenix in developing monoclonal antibodies targeting our protein. The antibodies they produced were not only highly selective but also demonstrated exceptional affinity for our target, significantly advancing our research. ProteoGenix impressed us with their efficiency and speed throughout the process. Their commitment to providing excellent customer service made our experience even better, as they were always available to address our questions and concerns. We highly recommend ProteoGenix to anyone in need of high-quality antibody development.”
Canopy Immuno-Therapeutics, Israel
Dr. Galit Denkberg, Vice-President Discovery
“We contacted ProteoGenix to develop repertoires of specific antibodies against three antigens sharing high homology. As determined by ELISA, ProteoGenix developed several specific antibodies that exhibited no cross-reactivity with the other antigens. We appreciated their proactive approach to increase our chances of success (e.g., performing fusions at their own risks). We are satisfied with the services of the company.”
Explore the latest advancements, expert insights, news shaping antibody research. From scientific publications and breakthrough innovations to upcoming webinars and exclusive content, stay informed and inspired. Gain the knowledge and tools you need to accelerate your discoveries.
Publication
H Cerutti et al., Large scale production and characterization of SARS-CoV-2 whole antigen for serological test development. J Clin Lab Anal 35, (4) 23735 (2021).
Read More
Webinar Replay
Proven strategies to boost your antibody expression Looking for effective strategies to optimize your transient protein & antibody production?
Watch now
Video
Q&A with experts: XtenCHO™ Race, the next generation mammalian transient expression system.
Watch
Handbook
Transient Protein Expression: Mammalian cell-based recombinant protein expression and purification technologies.
Get your free handbook
Custom Cell Line Development Find out why ProteoGenix is the trusted partner for custom cell line development.
M Pitaro et al., Development of a recombinant human IgG1 monoclonal antibody against the TRBV5-1 segment of the T cell receptor for the treatment of mature T cell neoplasms. Front Immunol 15, 1520103 (2024).
Dive into our most recent posts and discover insights, expert opinions, and breakthroughs in the world of life sciences and biotechnology.
Others
Oct 30, 2024
Antibody production
Oct 28, 2024
Customers success stories
Need a personalized consultation or a quote ? Message us and we will get back to you in less than 48 hours.
First Name*
Last Name*
Email*
Phone*
Lab/Company*
Message*
Submit
Your cart is currently empty.